Alnylam Pharms Inc patents expiration
1. Amvuttra patents expiration
AMVUTTRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(4 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
| US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(8 years from now) | |
| US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(8 years from now) | |
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US10683501 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(12 years from now) | |
| US11286486 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(12 years from now) | |
| US10208307 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
AMVUTTRA family patents
2. Givlaari patents expiration
GIVLAARI's oppositions filed in EPO
GIVLAARI Litigations
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of a target gene |
Jan, 2022
(2 years ago) | |
| US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(3 months ago) | |
| US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(a month ago) | |
| US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(a month ago) | |
| US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(21 days from now) | |
| US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(1 year, 4 months from now) | |
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(4 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
| US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) | |
| US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Nov, 2033
(9 years from now) | |
| US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(10 years from now) | |
| US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
GIVLAARI family patents
3. Onpattro patents expiration
ONPATTRO's oppositions filed in EPO
ONPATTRO Litigations
Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8895721 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US8552171 | ALNYLAM PHARMS INC | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(3 years ago) | |
| US8362231 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US8372968 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US8895718 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US9567582 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US8334373 | ALNYLAM PHARMS INC | Nuclease resistant double-stranded ribonucleic acid |
May, 2025
(1 year, 30 days from now) | |
| US8168775 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(5 years from now) | |
| US10240152 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(5 years from now) | |
| US11079379 | ALNYLAM PHARMS INC | Methods of treating transthyretin (TTR) mediated amyloidosis |
Aug, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778902 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(3 years ago) | |
| US9193753 | ALNYLAM PHARMS INC | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(3 years ago) | |
| US9943538 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(5 months ago) | |
| US9943539 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(5 months ago) | |
| US8642076 | ALNYLAM PHARMS INC | Lipid containing formulations |
Oct, 2027
(3 years from now) | |
| US11141378 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US9364435 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US8822668 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US8492359 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US8058069 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US8741866 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(5 years from now) | |
| US9234196 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(5 years from now) | |
| US8802644 | ALNYLAM PHARMS INC | Lipid formulation |
Oct, 2030
(6 years from now) | |
| US8158601 | ALNYLAM PHARMS INC | Lipid formulation |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
ONPATTRO family patents
4. Oxlumo patents expiration
Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(4 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(5 years from now) | |
| US10465195 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(10 years from now) | |
| US10487330 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(10 years from now) | |
| US11060093 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(10 years from now) | |
| US9828606 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(10 years from now) | |
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US10612027 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(11 years from now) | |
| US11446380 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Oct, 2035
(11 years from now) | |
| US10478500 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
Oct, 2035
(11 years from now) | |
| US11261447 | ALNYLAM PHARMS INC | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Nov, 2038
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10435692 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-339) | Nov 23, 2027 |
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2025 |
| Orphan Drug Exclusivity(ODE-415) | Oct 06, 2029 |
| New Indication(I-901) | Oct 06, 2025 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 23 November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
OXLUMO family patents